Vettore, LLC

Tolero Pharmaceuticals, Inc.

Sumitomo Dainippon Pharma Oncology, Inc.

Kenneth Mark Parnell

John Michael McCall

Koc-Kan Ho

Yong Xu

Jihua Liu

Xiaohui Liu

Michael David Saunders

Jason Marc Foulks

Kevin Bret Wright

Scott Albert Pearce

Steven Brian Kanner

David Lee Vollmer

Donna Lee Romero

John Mccall

John M Mccall

Micheal David Saunders

Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

Heterocyclic inhibitors of MCT4

Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.

MCT4 inhibitors for treating disease

Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I:  Methods of inhibition MCT4 activity in a human or animal subject are also provided.

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

PKM2 modulators and methods for their use

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Growing community of inventors

Kaysville, UT, United States of America

Kenneth Mark Parnell